Medicines Manufacturing Innovation Foundry
Tue, 16 Jan 2024
This event will bring together representatives from the pharmaceutical industry, funding agencies, regulators and, most importantly, innovators to highlight technological challenges faced by the pharmaceutical industry and showcase emerging technologies that may help address these challenges.
We are inviting innovators, including established SME’s, recent university spin-outs, and academics to showcase their technology at the event in a short pitch session — an opportunity to give a brief overview of the technology and highlight its potential applications and impact on pharmaceutical manufacturing.
As an innovator, you will receive valuable feedback on your technology from pharmaceutical industry and funding body experts, understand the opportunities for your technology, the risks to adoption, and gaps.
The event will occur over 3 days, with each day focussing on different areas:
Please register for the day(s) you would like to attend. We have a limited number of pitch slots and you are advised to register as soon as possible.
16th January 2024: Sustainability
The pharmaceutical industry has set ambitious targets to reduce its carbon footprint. The manufacture of drugs constitutes a significant portion of the carbon footprint of the industry and significant innovative action is required to improve the efficiency of manufacturing processes and reduce waste generated.
Specifically, the use of hydrocarbon derived materials such as organic solvents is highlighted as a significant contributor to the carbon footprint and technologies that can eliminate or reduce the quantities consumed will have a significant impact on the sustainability of the pharmaceutical business.
17th January 2024: New Modalities
Increasingly the pharmaceutical industry is moving away from traditional small molecules as potential therapeutic agents. Alternative molecule classes, such as oligonucleotides, peptides, mRNA and conjugates are increasingly being investigated for the development of new therapies. However, the manufacturing processes for production of these molecules is, relative to synthetic small molecules and biologics, underdeveloped and there is considerable scope to improve the manufacturing methods for these molecules.
18th January 2024: Digital
In order to meet the speed and compliance needs of the future pharma industry we need to digitalise. To determine how collaborative innovation can drive our pace in this area we will focus on driving standards (across data and systems) and robust implementation of new technology in both greenfield and brownfield sites, along with how we best share data in a secure way to drive process-prediction and sustainability outcomes.
The goal of this event is to increase the awareness among industry representatives of emerging technologies, understand areas of common interest with other companies, offer the opportunity to influence the direction of technology development, and identify technologies they believe will be of value to their business and discuss opportunities to develop them to commercial application
This event has been funded through Scottish Enterprise’s Ecosystem Fund, a programme to help deliver innovative and inclusive entrepreneurship support activities across Scotland and internationally